Filtered By:
Cancer: Lymphoma
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 25227 results found since Jan 2013.
Higher 13-Gene-Estimated TMB Detected from Plasma ctDNA is Associated with Worse Outcome for T-Cell Lymphoma Patients
Adv Biol (Weinh). 2023 Sep 1:e2300042. doi: 10.1002/adbi.202300042. Online ahead of print.ABSTRACTExome sequencing of in situ tumor samples reveals that mutated genes can predict the prognosis of patients with T-cell lymphoma (TCL). However, how tumor mutation burden (TMB) derived from circulating tumor DNA (ctDNA) may stratify TCL patients remains unclear.The plasma ctDNA of 79 newly diagnosed TCL patients from the clinical center is used for targeted exome sequencing, and the exome data of 4035 TCL patients from the Catalogue of Somatic Mutations in Cancer (COSMIC) database is obtained for comparison analysis.TCL patient...
Source: Adv Data - September 2, 2023 Category: Epidemiology Authors: Cunte Chen Ling Huang Zheng Chen Qiuxiang Ou Sichu Liu Xinmiao Jiang Feili Chen Xiaojuan Wei Hanguo Guo Yang Shao Chengwu Zeng Yangqiu Li Wenyu Li Source Type: research
Repeated deep-inspiration breath-hold CT scans at planning underestimate the actual motion between breath-holds at treatment for lung cancer and lymphoma patients
Conclusion Intra-DIBH shifts at planning-CT session are generally smaller than intra-DIBH shifts observed at CBCTpre/post and therefore underestimate the intra-fractional DIBH uncertainty during treatment. Lung tumours show larger intra-fractional variations than lymph nodes and lymphoma targets.PMID:37659663 | DOI:10.1016/j.radonc.2023.109887
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - September 2, 2023 Category: Radiology Authors: L Hoffmann M L Ehmsen J Hansen R Hansen M M Knap H R Mortensen P R Poulsen T Ravkilde H K Rose H H Schmidt E S Worm D S M øller Source Type: research
Disparities in Multiple Myeloma Treatment Patterns in the United States: A Systematic Review
Clin Lymphoma Myeloma Leuk. 2023 Aug 13:S2152-2650(23)00255-0. doi: 10.1016/j.clml.2023.08.008. Online ahead of print.ABSTRACTWe performed a systematic review of the literature investigating the demographic and insurance-related factors linked to disparities in multiple myeloma (MM) care patterns in the United States from 2003 to 2021. Forty-six observational studies were included. Disparities in MM care patterns were reported based on patient race in 76% of studies (34 out of 45 that captured race as a study variable), ethnicity in 60% (12 out of 20), insurance in 77% (17 out of 22), and distance from treating facility, u...
Source: Clinical Lymphoma and Myeloma - September 2, 2023 Category: Cancer & Oncology Authors: Hamlet Gasoyan Mark A Fiala Michelle Doering Ravi Vij Michael Halpern Graham A Colditz Source Type: research
Clinicopathologic Features of Cutaneous T-Cell Lymphomas With Extracutaneous Metastasis: A Case Series
CONCLUSION: To the best of our knowledge, there are limited studies analyzing the clinicopathologic features of different CTCL entities with metastasis as a single population. This research provides valuable insights into the unique characteristics of metastatic CTCL.PMID:37659965 | DOI:10.1016/j.clml.2023.08.006
Source: Clinical Lymphoma and Myeloma - September 2, 2023 Category: Cancer & Oncology Authors: Haiming Tang Nana Matsumoto Francine Foss Mina Xu Aadil Ahmed Source Type: research
Bcl-6 expression by CD4 < sup > + < /sup > T cells determines concomitant immunity and host resistance across distinct parasitic infections
Mucosal Immunol. 2023 Aug 31:S1933-0219(23)00066-1. doi: 10.1016/j.mucimm.2023.08.004. Online ahead of print.ABSTRACTCD4+ T cells consist of multiple subtypes, defined by expression of lineage-specific transcription factors, that contribute to the control of infectious diseases by providing help to immune and non-immune target cells. In the current study, we examined the role of B cell lymphoma (Bcl)-6, a transcriptional repressor and master regulator of T follicular helper cell differentiation, in T cell-mediated host defense against intestinal and systemic parasitic infections. We demonstrate that while Bcl-6 expression ...
Source: Cancer Control - September 2, 2023 Category: Cancer & Oncology Authors: Alexandre P Meli Gabriel A Russell Sharada Swaminathan Laura Weichselbaum Clara A MacMahon Erwan Pernet Danielle Karo-Atar Dakota Rogers Annie Rochette Ghislaine Fontes Judith N Mandl Maziar Divangahi Ophir D Klein Alex Gregorieff Simona St äger Irah L K Source Type: research
Higher 13-Gene-Estimated TMB Detected from Plasma ctDNA is Associated with Worse Outcome for T-Cell Lymphoma Patients
Adv Biol (Weinh). 2023 Sep 1:e2300042. doi: 10.1002/adbi.202300042. Online ahead of print.ABSTRACTExome sequencing of in situ tumor samples reveals that mutated genes can predict the prognosis of patients with T-cell lymphoma (TCL). However, how tumor mutation burden (TMB) derived from circulating tumor DNA (ctDNA) may stratify TCL patients remains unclear.The plasma ctDNA of 79 newly diagnosed TCL patients from the clinical center is used for targeted exome sequencing, and the exome data of 4035 TCL patients from the Catalogue of Somatic Mutations in Cancer (COSMIC) database is obtained for comparison analysis.TCL patient...
Source: Cancer Control - September 2, 2023 Category: Cancer & Oncology Authors: Cunte Chen Ling Huang Zheng Chen Qiuxiang Ou Sichu Liu Xinmiao Jiang Feili Chen Xiaojuan Wei Hanguo Guo Yang Shao Chengwu Zeng Yangqiu Li Wenyu Li Source Type: research
Repeated deep-inspiration breath-hold CT scans at planning underestimate the actual motion between breath-holds at treatment for lung cancer and lymphoma patients
Conclusion Intra-DIBH shifts at planning-CT session are generally smaller than intra-DIBH shifts observed at CBCTpre/post and therefore underestimate the intra-fractional DIBH uncertainty during treatment. Lung tumours show larger intra-fractional variations than lymph nodes and lymphoma targets.PMID:37659663 | DOI:10.1016/j.radonc.2023.109887
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - September 2, 2023 Category: Radiology Authors: L Hoffmann M L Ehmsen J Hansen R Hansen M M Knap H R Mortensen P R Poulsen T Ravkilde H K Rose H H Schmidt E S Worm D S M øller Source Type: research
Serum levels of vault RNA significantly varied in patients with haematological malignancies
Mol Med Rep. 2023 Oct;28(4):190. doi: 10.3892/mmr.2023.13077. Epub 2023 Sep 1.ABSTRACTAmong extracellular non‑coding RNAs, serum levels of microRNAs have been extensively investigated in cancers. In contrast, the serum levels of vault RNAs (vtRNAs) in relation to various disease conditions remain poorly understood. The present study evaluated the clinical significance of serum vtRNA1‑1 levels in patients with blood diseases. The stability and sub‑localisation of serum vtRNA1‑1 was assessed and a reverse transcription‑quantitative PCR method using spiked RNA to quantify serum vtRNA1‑1 was developed. Serum vtRNA1...
Source: Molecular Medicine - September 1, 2023 Category: Molecular Biology Authors: Haruka Kato Yuki Hashimoto Yuki Hatayama Hisashi Shimohiro Toru Motokura Source Type: research
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia
J Cell Mol Med. 2023 Aug 31. doi: 10.1111/jcmm.17868. Online ahead of print.ABSTRACTMantle-cell lymphoma (MCL) is a B-cell non-Hodgkin Lymphoma (NHL) with a poor prognosis, at high risk of relapse after conventional treatment. MCL-associated tumour microenvironment (TME) is characterized by M2-like tumour-associated macrophages (TAMs), able to interact with cancer cells, providing tumour survival and resistance to immuno-chemotherapy. Likewise, monocyte-derived nurse-like cells (NLCs) present M2-like profile and provide proliferation signals to chronic lymphocytic leukaemia (CLL), a B-cell malignancy sharing with MCL some ...
Source: Molecular Medicine - September 1, 2023 Category: Molecular Biology Authors: Andrea Aroldi Mario Mauri Daniele Ramazzotti Matteo Villa Federica Malighetti Valentina Crippa Federica Cocito Chiara Borella Elisa Bossi Carolina Steidl Chiara Scollo Claudia Voena Roberto Chiarle Luca Mologni Rocco Piazza Carlo Gambacorti-Passerini Source Type: research
Proteomics-Based Discovery of First-in-Class Chemical Probes for Programmed Cell Death Protein 2 (PDCD2)
Angew Chem Int Ed Engl. 2023 Sep 1:e202308292. doi: 10.1002/anie.202308292. Online ahead of print.ABSTRACTChemical probes are essential tools for understanding biological systems and for credentialing potential biomedical targets. Programmed cell death 2 (PDCD2) is a member of the B-cell lymphoma 2 (Bcl-2) family of proteins, which are critical regulators of apoptosis. Here we report the discovery and characterization of 10e, a first-in-class small molecule degrader of PDCD2. We discovered PDCD2 degrader by serendipity using a chemical proteomics approach in contrast to the conventional approach for making bivalent degrade...
Source: Angewandte Chemie - September 1, 2023 Category: Chemistry Authors: Wenzhi Ji Woong Sub Byun Wenchao Lu Xijun Zhu Katherine A Donovan Brendan Dwyer Jianwei Che Linjie Yuan Xianmixinuer Abulaiti Steven M Corsello Eric S Fischer Tinghu Zhang Nathanael Schiander Gray Source Type: research
Non-coding RNAs in the epigenetic landscape of cutaneous T-cell lymphoma
Int Rev Cell Mol Biol. 2023;380:149-171. doi: 10.1016/bs.ircmb.2023.04.004. Epub 2023 Jul 21.ABSTRACTCutaneous T-cell lymphoma (CTCL) is a type of cancer that affects skin, and is characterized by abnormal T-cells in the skin. Epigenetic changes have been found to play a significant role in the development and progression of CTCL. Recently, non-coding RNAs (ncRNAs), such as microRNAs and long non-coding RNAs, have been identified as key players in the regulation of gene expression in CTCL. These ncRNAs can alter the expression of genes involved in cell growth, differentiation, and apoptosis, leading to the development and ...
Source: Mol Biol Cell - September 1, 2023 Category: Molecular Biology Authors: Monaza Adeeb Lubna Therachiyil Safwan Moton Joerg Buddenkotte Majid Ali Alam Shahab Uddin Martin Steinhoff Aamir Ahmad Source Type: research
Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan
CONCLUSIONS: This study suggests that Pola + R-CHP is a cost-effective treatment for previously untreated DLBCL in Japan under the public health insurance system.PMID:37656225 | DOI:10.1080/13696998.2023.2254162
Source: Journal of Medical Economics - September 1, 2023 Category: Health Management Authors: Takashi Mizuoka Hiroyuki Sakamaki Shigeo Fuji Shota Saito Tatsunori Murata Shinya Ohno Naoki Inubashiri Tomoha Oshima Kazuhito Yamamoto Source Type: research
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia
J Cell Mol Med. 2023 Aug 31. doi: 10.1111/jcmm.17868. Online ahead of print.ABSTRACTMantle-cell lymphoma (MCL) is a B-cell non-Hodgkin Lymphoma (NHL) with a poor prognosis, at high risk of relapse after conventional treatment. MCL-associated tumour microenvironment (TME) is characterized by M2-like tumour-associated macrophages (TAMs), able to interact with cancer cells, providing tumour survival and resistance to immuno-chemotherapy. Likewise, monocyte-derived nurse-like cells (NLCs) present M2-like profile and provide proliferation signals to chronic lymphocytic leukaemia (CLL), a B-cell malignancy sharing with MCL some ...
Source: J Cell Mol Med - September 1, 2023 Category: Molecular Biology Authors: Andrea Aroldi Mario Mauri Daniele Ramazzotti Matteo Villa Federica Malighetti Valentina Crippa Federica Cocito Chiara Borella Elisa Bossi Carolina Steidl Chiara Scollo Claudia Voena Roberto Chiarle Luca Mologni Rocco Piazza Carlo Gambacorti-Passerini Source Type: research
Efficacy of single-agent chemotherapy with pegylated liposomal doxorubicin or gemcitabine in a diverse cohort of patients with recalcitrant cutaneous T-cell lymphoma
Br J Dermatol. 2023 Sep 1:ljad311. doi: 10.1093/bjd/ljad311. Online ahead of print.NO ABSTRACTPMID:37655919 | DOI:10.1093/bjd/ljad311
Source: The British Journal of Dermatology - September 1, 2023 Category: Dermatology Authors: David Weiner Andrew Ly Sai Talluru Ananya Munjal Olivia Pierog Richard Ambinder Sima Rozati Source Type: research
Non-coding RNAs in the epigenetic landscape of cutaneous T-cell lymphoma
Int Rev Cell Mol Biol. 2023;380:149-171. doi: 10.1016/bs.ircmb.2023.04.004. Epub 2023 Jul 21.ABSTRACTCutaneous T-cell lymphoma (CTCL) is a type of cancer that affects skin, and is characterized by abnormal T-cells in the skin. Epigenetic changes have been found to play a significant role in the development and progression of CTCL. Recently, non-coding RNAs (ncRNAs), such as microRNAs and long non-coding RNAs, have been identified as key players in the regulation of gene expression in CTCL. These ncRNAs can alter the expression of genes involved in cell growth, differentiation, and apoptosis, leading to the development and ...
Source: International Review of Cell and Molecular Biology - September 1, 2023 Category: Cytology Authors: Monaza Adeeb Lubna Therachiyil Safwan Moton Joerg Buddenkotte Majid Ali Alam Shahab Uddin Martin Steinhoff Aamir Ahmad Source Type: research
